These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

751 related items for PubMed ID: 18929236

  • 21. Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk.
    Lazar LD, Lincoff AM.
    Cleve Clin J Med; 2009 Dec; 76(12):707-14. PubMed ID: 19952295
    [Abstract] [Full Text] [Related]

  • 22. Thienopyridine antiplatelet agents: focus on prasugrel.
    Freeman MK.
    Consult Pharm; 2010 Apr; 25(4):241-57. PubMed ID: 20511177
    [Abstract] [Full Text] [Related]

  • 23. Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
    Tcheng JE, Mackay SM.
    Am J Cardiovasc Drugs; 2012 Apr 01; 12(2):83-91. PubMed ID: 22316323
    [Abstract] [Full Text] [Related]

  • 24. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes.
    Baker WL, White CM.
    Am J Cardiovasc Drugs; 2009 Apr 01; 9(4):213-29. PubMed ID: 19655817
    [Abstract] [Full Text] [Related]

  • 25. A comparison of the metabolism of clopidogrel and prasugrel.
    Laizure SC, Parker RB.
    Expert Opin Drug Metab Toxicol; 2010 Nov 01; 6(11):1417-24. PubMed ID: 20839914
    [Abstract] [Full Text] [Related]

  • 26. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
    Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, Van de Werf F, Downey WE, Scirica BM, Murphy SA, Antman EM, TRITON-TIMI 38 Investigators.
    Lancet; 2008 Apr 19; 371(9621):1353-63. PubMed ID: 18377975
    [Abstract] [Full Text] [Related]

  • 27. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
    Michelson AD, Frelinger AL, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD, TRITON-TIMI 38 Investigators.
    Eur Heart J; 2009 Jul 19; 30(14):1753-63. PubMed ID: 19435740
    [Abstract] [Full Text] [Related]

  • 28. Oral antiplatelet therapy for the management of acute coronary syndromes: defining the role of prasugrel.
    Devabhakthuni S, Seybert AL.
    Crit Care Nurse; 2011 Feb 19; 31(1):51-63. PubMed ID: 20592188
    [Abstract] [Full Text] [Related]

  • 29. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, Martinez F, Dalby AJ, Boden WE, White HD, Prabhakaran D, Winters KJ, Aylward PE, Bassand JP, McGuire DK, Ardissino D, Fox KA, Armstrong PW.
    Circulation; 2013 Aug 20; 128(8):823-33. PubMed ID: 23852610
    [Abstract] [Full Text] [Related]

  • 30. Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.
    Martin MT, Spinler SA, Nutescu EA.
    Clin Ther; 2011 Apr 20; 33(4):425-42. PubMed ID: 21635989
    [Abstract] [Full Text] [Related]

  • 31. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.
    Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM, TRITON-TIMI 38 Investigators.
    Circulation; 2008 Oct 14; 118(16):1626-36. PubMed ID: 18757948
    [Abstract] [Full Text] [Related]

  • 32. Current oral antiplatelets: focus update on prasugrel.
    John J, Koshy SK.
    J Am Board Fam Med; 2012 Oct 14; 25(3):343-9. PubMed ID: 22570398
    [Abstract] [Full Text] [Related]

  • 33. Novel antiplatelet strategies in acute coronary syndromes.
    Sabatine MS.
    Cleve Clin J Med; 2009 Apr 14; 76 Suppl 1():S8-15. PubMed ID: 19332592
    [Abstract] [Full Text] [Related]

  • 34. Prasugrel: a new antiplatelet drug for the prevention and treatment of cardiovascular disease.
    Koo MH, Nawarskas JJ, Frishman WH.
    Cardiol Rev; 2008 Apr 14; 16(6):314-8. PubMed ID: 18923235
    [Abstract] [Full Text] [Related]

  • 35. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.
    Jakubowski JA, Winters KJ, Naganuma H, Wallentin L.
    Cardiovasc Drug Rev; 2007 Apr 14; 25(4):357-74. PubMed ID: 18078435
    [Abstract] [Full Text] [Related]

  • 36. Review of prasugrel for the secondary prevention of atherothrombosis.
    Spinler SA, Rees C.
    J Manag Care Pharm; 2009 Jun 14; 15(5):383-95. PubMed ID: 19496635
    [Abstract] [Full Text] [Related]

  • 37. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT, Regal RE, Dorsch MP.
    Ann Pharmacother; 2008 Apr 14; 42(4):550-7. PubMed ID: 18319394
    [Abstract] [Full Text] [Related]

  • 38. Antiplatelet options for secondary prevention in acute coronary syndromes.
    Silvain J, Cayla G, O'Connor SA, Collet JP, Montalescot G.
    Expert Rev Cardiovasc Ther; 2011 Nov 14; 9(11):1403-15. PubMed ID: 22059790
    [Abstract] [Full Text] [Related]

  • 39. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
    Steinhubl S, Roe MT.
    Cardiovasc Drug Rev; 2007 Nov 14; 25(2):188-203. PubMed ID: 17614940
    [Abstract] [Full Text] [Related]

  • 40. Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel.
    Salisbury AC, Wang K, Cohen DJ, Li Y, Jones PG, Spertus JA.
    Circ Cardiovasc Qual Outcomes; 2013 Jan 01; 6(1):27-34. PubMed ID: 23212457
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.